Literature DB >> 7994819

Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis.

S P Friedrich1, B H Lorell, M F Rousseau, W Hayashida, O M Hess, P S Douglas, S Gordon, C S Keighley, C Benedict, H P Krayenbuehl.   

Abstract

BACKGROUND: Cardiac hypertrophy is associated with elevated intracardiac angiotensin-converting enzyme activity, which may contribute to diastolic dysfunction. METHODS AND
RESULTS: We infused enalaprilat (0.05 mg/min) for 15 minutes into the left coronary arteries of 20 adult patients with left ventricular (LV) hypertrophy due to aortic stenosis (mean aortic valve area, 0.7 +/- 0.2 cm2) and 10 patients with dilated cardiomyopathy (mean ejection fraction, 35 +/- 4%) and assessed (1) simultaneous changes in LV micromanometer pressure and dimensions, (2) LV regional wall motion analyzed by the area method, and (3) Doppler flow-velocity profiles. Systemic neurohormonal activation did not occur with the selective left coronary artery infusion; there were no changes in plasma renin activity, angiotensin-converting enzyme activity, or atrial natriuretic peptide. In patients with aortic stenosis, LV end-diastolic pressure declined from 25 +/- 2 to 20 +/- 2 mm Hg (P < .05). LV pressure-volume and LV pressure-dimension relations showed downward shifts by ventriculography and echocardiography, respectively, indicating improved diastolic distensibility. Regional area change during isovolumic relaxation increased in the anterior segments perfused with enalaprilat but decreased in the inferior segments, indicating acceleration of isovolumic relaxation in the anterior segments and reciprocal shortening in the inferior segments. Regional peak filling rate increased in the anterior segments but not in the inferior segments, and the regional area stiffness constant decreased in the anterior segments but not in the inferior segments. There were no changes in heart rate, cardiac output, or right atrial pressure, excluding alterations in right ventricular/pericardial constraint. In contrast, in the patients with dilated cardiomyopathy the decrease in LV end-diastolic pressure from 22 +/- 2 to 18 +/- 2 mm Hg (P < .05) was accompanied by a significant fall in right atrial pressure (9 +/- 1 to 6 +/- 1 mm Hg), implicating alterations in pericardial constraint. The patients with dilated cardiomyopathy showed no improvement in regional diastolic relaxation, filling, or distensibility.
CONCLUSIONS: Intracoronary enalaprilat at a dosage that did not cause systemic neurohormonal activation improved LV diastolic chamber distensibility and regional relaxation and filling in patients with LV hypertrophy due to aortic stenosis. In contrast, these effects of intracoronary enalaprilat on diastolic function were not observed in patients with dilated cardiomyopathy who did not have concentric hypertrophy. These observations support the hypothesis that the cardiac renin-angiotensin system is activated in patients with concentric pressure-overload hypertrophy and that this activation may contribute to impaired diastolic function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994819     DOI: 10.1161/01.cir.90.6.2761

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

Review 2.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

3.  Reduced atrial angiotensin receptor type 1 mRNA content in end-stage human heart failure: assessment by a novel quantitative PCR-ELISA technique.

Authors:  P Bauer; V Regitz-Zagrosek; J Hofmeister; J Lokies; A Rolfs; A G Hildebrandt; R Hetzer; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

Review 4.  Diastolic dysfunction as a cause of exercise intolerance.

Authors:  W C Little; D W Kitzman; C P Cheng
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

5.  Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.

Authors:  K Stamatelopoulos; D Bramos; E Manios; E Alexaki; A Kaladaridou; G Georgiopoulos; E Koroboki; A Kolyviras; K Stellos; N Zakopoulos; S Toumanidis
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

6.  Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload.

Authors:  Ricardo J Gelpi; Shumin Gao; Peiyong Zhai; Lin Yan; Chull Hong; Lauren M A Danridge; Hui Ge; Yasahiro Maejima; Martin Donato; Mitsuhiro Yokota; Jeffery D Molkentin; Dorothy E Vatner; Stephen F Vatner; Junichi Sadoshima
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

7.  Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix.

Authors:  Matthew K Stephenson; Sean Lenihan; Roman Covarrubias; Ryan M Huttinger; Richard J Gumina; Douglas B Sawyer; Cristi L Galindo
Journal:  J Vis Exp       Date:  2016-06-14       Impact factor: 1.355

Review 8.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

9.  Renin-Angiotensin System Genes Polymorphisms and Long-Term Prognosis in Taiwanese Patients with Hypertension and Coronary Artery Disease.

Authors:  Cho-Kai Wu; Jen-Kuang Lee; Lian-Yu Lin; Yin-Tsen Huang; Juey-Jen Hwang; Chunn-Lee Lin; Chuen-Den Tseng; Fu-Tien Chiang
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

10.  Management of asymptomatic severe aortic stenosis.

Authors:  Robert L Stewart; Kwan L Chan
Journal:  Curr Cardiol Rev       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.